Fc Engineering Approaches to Enhance the Agonism and Effector Functions of an Anti-OX40 Antibody

A Novel Platform for the Potentiation of Therapeutic Antibodies Based on Antigen-Dependent Formation of IgG Hexamers at the Cell Surface

(2016) Rob N. de Jong et al.   PLOS BIOLOGY

Conformation of the Human Immunoglobulin G2 Hinge Imparts Superagonistic Properties to Immunostimulatory Anticancer Antibodies

(2015) Ann L. White et al.   CANCER CELL

Characterization of the human T cell response to in vitro CD27 costimulation with varlilumab

(2015) Venky Ramakrishna et al.   Journal for ImmunoTherapy of Cancer

The Human Agonistic CD40 Antibody ADC-1013 Eradicates Bladder Tumors and Generates T-cell-Dependent Tumor Immunity

(2014) S. M. Mangsbo et al.   CLINICAL CANCER RESEARCH

OX40 engagement depletes intratumoral Tregs via activating FcγRs, leading to antitumor efficacy

(2014) Yannick Bulliard et al.   IMMUNOLOGY AND CELL BIOLOGY

Complement Is Activated by IgG Hexamers Assembled at the Cell Surface

(2014) C. A. Diebolder et al.   SCIENCE

Targeting tumor-necrosis factor receptor pathways for tumor immunotherapy

(2014) David A Schaer et al.   Journal for ImmunoTherapy of Cancer

The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy

(2013) Amy E Moran et al.   CURRENT OPINION IN IMMUNOLOGY

Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies

(2013) Yannick Bulliard et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Agonist Anti-Human CD27 Monoclonal Antibody Induces T Cell Activation and Tumor Immunity in Human CD27-Transgenic Mice

(2013) L.-Z. He et al.   JOURNAL OF IMMUNOLOGY

Engineered antibody Fc variant with selectively enhanced Fc RIIb binding over both Fc RIIaR131 and Fc RIIaH131

(2013) F. Mimoto et al.   PROTEIN ENGINEERING DESIGN & SELECTION

A general requirement for FcγRIIB co-engagement of agonistic anti-TNFR antibodies

(2012) Fubin Li et al.   CELL CYCLE

OX40 signaling favors the induction of TH9 cells and airway inflammation

(2012) Xiang Xiao et al.   NATURE IMMUNOLOGY

Apoptotic and antitumor activity of death receptor antibodies require inhibitory Fc  receptor engagement

(2012) F. Li et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

An Fcγ Receptor-Dependent Mechanism Drives Antibody-Mediated Target-Receptor Signaling in Cancer Cells

(2011) Nicholas S. Wilson et al.   CANCER CELL

Interaction with Fc RIIB Is Critical for the Agonistic Activity of Anti-CD40 Monoclonal Antibody

(2011) A. L. White et al.   JOURNAL OF IMMUNOLOGY

Cancer immunotherapy comes of age

(2011) Ira Mellman et al.   NATURE

Inhibitory Fc  Receptor Engagement Drives Adjuvant and Anti-Tumor Activities of Agonistic CD40 Antibodies

(2011) F. Li et al.   SCIENCE

Dimers and multimers of monoclonal IgG1 exhibit higher in vitro binding affinities to Fcγ receptors

(2010) Yin Luo et al.   mAbs

Inhibition of B cell receptor-mediated activation of primary human B cells by coengagement of CD19 and FcγRIIb with Fc-engineered antibodies

(2008) Seung Y. Chu et al.   MOLECULAR IMMUNOLOGY